



Consolidated Financial Statements

For the Years Ended December 31, 2012 and 2011

## *Table of Contents*

---

	<i>Page</i>
<b>Independent Auditors' Report</b>	1 - 2
<b>Consolidated Financial Statements:</b>	
Consolidated Statements of Financial Position	3
Consolidated Statements of Unrestricted Activities	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7 - 25

***Independent Auditors' Report******Board of Directors  
Program for Appropriate Technology in Health (PATH)  
Seattle, Washington***

We have audited the accompanying consolidated financial statements of Program for Appropriate Technology in Health (PATH) and Subsidiaries (collectively, the Organization) which comprise the consolidated statements of financial position as of December 31, 2012 and 2011, and the related consolidated statements of unrestricted activities, changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

***Auditors' Responsibility***

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

# CLARK NUBER

## *Opinion*

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of December 31, 2012 and 2011, and the changes in its net assets and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Certified Public  
Accountants  
and Consultants

*Clark Nuber P.S.*

Certified Public Accountants  
May 10, 2013

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Consolidated Statements of Financial Position**  
**December 31, 2012 and 2011**  
**(In Thousands)**

	<u>2012</u>	<u>2011</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 40,453	\$ 18,222
Investments	275,355	298,871
Contributions and awards receivable, net	333,178	399,183
Prepaid expenses and other	2,777	2,775
Other receivables	2,437	3,234
Furniture, equipment and leasehold improvements, net	20,812	22,080
Patent, net	403	582
<b>Total Assets</b>	<b><u>\$ 675,415</u></b>	<b><u>\$ 744,947</u></b>
<b>Liabilities and Net Assets</b>		
Accounts payable	\$ 28,142	\$ 37,956
Accrued expenses and other liabilities	26,401	24,122
Notes payable	5,232	5,980
<b>Total Liabilities</b>	<b>59,775</b>	<b>68,058</b>
<b>Net Assets:</b>		
Unrestricted	21,281	17,629
Temporarily restricted	590,984	655,890
Permanently restricted	3,375	3,370
<b>Total Net Assets</b>	<b><u>615,640</u></b>	<b><u>676,889</u></b>
<b>Total Liabilities and Net Assets</b>	<b><u>\$ 675,415</u></b>	<b><u>\$ 744,947</u></b>

See accompanying notes.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Consolidated Statements of Unrestricted Activities  
For the Years Ended December 31, 2012 and 2011  
(In Thousands)**

	<u>2012</u>	<u>2011</u>
<b>Revenues, Gains and Other Support:</b>		
Contributions and awards - government, international, agencies, foundations, and public and private funders-		
Contributions and awards released from restriction	\$ 306,655	\$ 277,081
Unrestricted private contributions	3,602	5,327
	<u>310,257</u>	<u>282,408</u>
Other income-		
Investment income	1,912	852
Program service income	27	80
License and royalty income	9	11
Gain on foreign currency exchange	381	219
Other	233	268
	<u>2,562</u>	<u>1,430</u>
<b>Total Revenues, Gains and Other Support</b>	<b>312,819</b>	<b>283,838</b>
<b>Expenses:</b>		
Program services-		
Vaccines and immunizations	112,071	121,301
Emerging and epidemic diseases	96,944	72,911
Health technologies	23,905	19,889
Maternal and child health	20,015	17,930
Reproductive health	11,684	11,936
Cross program	3,156	1,357
	<u>267,775</u>	<u>245,324</u>
Support services-		
Fundraising	1,503	1,430
Bid and proposal	1,719	1,963
Management and general	38,599	35,641
	<u>41,821</u>	<u>39,034</u>
<b>Total Expenses</b>	<b>309,596</b>	<b>284,358</b>
<b>Change in Unrestricted Net Assets</b>		
<b>Before Inherent Contribution from Acquisition</b>	<b>3,223</b>	<b>(520)</b>
Inherent contribution from acquisition	429	
<b>Change in Unrestricted Net Assets</b>	<b>\$ 3,652</b>	<b>\$ (520)</b>

See accompanying notes.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Consolidated Statements of Changes in Net Assets  
For the Years Ended December 31, 2012 and 2011  
(In Thousands)**

	<u>2012</u>	<u>2011</u>
<b>Unrestricted Net Assets:</b>		
Contributions and awards released from restrictions	\$ 306,655	\$ 277,081
Total unrestricted revenues, gains, and other support	6,164	6,757
Inherent contribution from acquisition	429	
Total expenses	<u>(309,596)</u>	<u>(284,358)</u>
<b>Change in Unrestricted Net Assets</b>	<b>3,652</b>	<b>(520)</b>
<b>Temporarily Restricted Net Assets:</b>		
Contributions and awards	202,933	246,640
Inherent contribution from acquisition	34,921	
Investment income	3,895	1,416
Contributions and awards released from restrictions	<u>(306,655)</u>	<u>(277,081)</u>
<b>Change in Temporarily Restricted Net Assets</b>	<b>(64,906)</b>	<b>(29,025)</b>
<b>Permanently Restricted Net Assets:</b>		
Contributions	<u>5</u>	<u>3</u>
<b>Change in Permanently Restricted Net Assets</b>	<b>5</b>	<b>3</b>
<b>Total Change in Net Assets</b>	<b>(61,249)</b>	<b>(29,542)</b>
Net assets, beginning of year	<u>676,889</u>	<u>706,431</u>
<b>Net Assets, End of Year</b>	<b><u>\$ 615,640</u></b>	<b><u>\$ 676,889</u></b>

See accompanying notes.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Consolidated Statements of Cash Flows**  
**For the Years Ended December 31, 2012 and 2011**  
**(In Thousands)**

	<u>2012</u>	<u>2011</u>
<b>Cash Flows from Operating Activities:</b>		
Change in net assets	\$ (61,249)	\$ (29,542)
Adjustments to reconcile change in net assets to net cash used by operating activities-		
Depreciation and amortization	3,894	3,441
Unrealized (gain) loss on investments	(2,213)	1,972
Loss on sale and disposal of equipment	158	93
Inherent contribution from acquisition	(35,350)	
Contributions restricted for endowment	(5)	(3)
Changes in assets and liabilities:		
Contributions and awards receivable	79,325	(854)
Prepaid expenses and other	418	(438)
Other receivables	797	(731)
Accounts payable	(10,856)	4,609
Accrued expenses and other liabilities	1,739	3,417
<b>Net Cash Used by Operating Activities</b>	<b>(23,342)</b>	<b>(18,036)</b>
<b>Cash Flows from Investing Activities:</b>		
Purchases of furniture, equipment and leasehold improvements	(2,492)	(5,459)
Proceeds from sale of equipment	34	98
Cash assumed from acquisition	3,138	
Purchases of investments	(37,289)	(69,774)
Proceeds from maturity/sales of investments	82,925	78,384
<b>Net Cash Provided by Investing Activities</b>	<b>46,316</b>	<b>3,249</b>
<b>Cash Flows from Financing Activities:</b>		
Payments on notes payable	(748)	(734)
Proceeds from contributions restricted for endowment	5	3
<b>Net Cash Used by Financing Activities</b>	<b>(743)</b>	<b>(731)</b>
<b>Net Change in Cash and Cash Equivalents</b>	<b>22,231</b>	<b>(15,518)</b>
Cash and cash equivalents, beginning of year	18,222	33,740
<b>Cash and Cash Equivalents, End of Year</b>	<b>\$ 40,453</b>	<b>\$ 18,222</b>
<b>Supplemental Disclosure of Cash Flow Information:</b>		
Cash paid during the year for interest	\$ 102	\$ 124

See accompanying notes.



## ***PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES***

### ***Notes to Consolidated Financial Statements***

***For the Years Ended December 31, 2012 and 2011***

---

#### ***Note 1 - Organization and Summary of Accounting Policies***

**Organization** - Program for Appropriate Technology in Health (PATH) and its Subsidiaries (collectively, the Organization) is a 501(c)(3) nonprofit, nongovernmental organization incorporated in the State of Washington. PATH creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH's work improves global health and well-being.

Headquartered in Seattle, PATH has offices in 41 cities in 21 countries. PATH currently works in more than 70 countries in the areas of health technologies, maternal and child health, reproductive health, vaccines and immunization, and emerging and epidemic diseases. For more information, please visit [www.path.org](http://www.path.org).

During 2011, PATH formed two new controlled subsidiaries: Organization for Appropriate Technologies in Health (OATH), a Ukrainian international nongovernmental organization; and Foundation for Appropriate Technologies in Health - Switzerland (FATH), a Swiss Foundation. Both entities were organized for the purpose of furthering PATH's exempt mission and purpose.

On January 1, 2012, PATH acquired PATH Drug Solutions (PDS), a controlled subsidiary (Note 17). PDS was previously known as Institute for OneWorld Health.

**Basis of Presentation** - The consolidated financial statements of the Organization have been prepared on the accrual basis of accounting under United States generally accepted accounting principles (U.S. GAAP). The consolidated financial statements include the accounts of PATH and PATH's wholly-owned subsidiaries, including PATH Vaccine Solutions (PVS), a 501(c)(3) nonprofit corporation formed to advance the development of vaccines to improve the health of children worldwide, OATH, FATH and PDS. All intercompany accounts and transactions have been eliminated in consolidation.

Net assets and revenue, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Organization are classified and reported as follows:

Unrestricted Net Assets - Net assets that are not subject to donor-imposed stipulations.

Temporarily Restricted Net Assets - Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Organization and/or the passage of time.

Permanently Restricted Net Assets - Net assets restricted by donor-imposed stipulations to be invested in perpetuity. The investment income from these funds is available for current use.

Support and revenue are reported as increases in unrestricted net assets unless the use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Temporary restrictions expire when the donor-stipulated purpose has been fulfilled and/or the donor-stipulated time period has elapsed. Expirations of temporary restrictions result in the reclassification of temporarily restricted net assets to unrestricted net assets and are reported in the consolidated statement of unrestricted activities as contributions and awards released from restrictions.

## ***PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES***

### ***Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011***

---

#### ***Note 1 - Continued***

**Cash and Cash Equivalents** - For purposes of the consolidated statements of cash flows, the Organization considers all highly liquid debt instruments purchased with an original maturity of three months or less, other than those held in the Organization's investment portfolio, to be cash equivalents.

**Investments** - Investments in equity securities with readily determinable market values and all debt securities are recorded at fair value. Unrealized and realized gains and losses on these investments are reported in the consolidated statements of activities and changes in net assets. Securities are generally held in custodial investment accounts administered by certain financial institutions.

Investment securities, in general, are exposed to various risks, including interest rate, credit and overall market volatility. Due to the level of risk associated with certain long-term investments, it is possible that changes in the values of these investments will occur in the near term and that such changes could materially affect the amounts reported in the consolidated statements of financial position.

Investment return consists primarily of income earned on cash, cash equivalents and investments, and is recorded as earned. Where directed by the donor or grantor, interest earned on award advances is credited to a specific restricted fund for future use as specified in the award agreement. All other interest income earned is credited to other restricted and unrestricted fund balances as is appropriate.

**Fair Value of Financial Instruments** - Financial instruments reported at fair value on a recurring basis include investments. Financial instruments not reported at fair value on a recurring basis include receivables, accounts payable and notes payable. The carrying amounts of these financial instruments approximate fair value.

**Contributions and Awards Receivable** - Contributions and awards receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncollectible amounts through a charge to change in net assets and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts, grants or contributions receivable.

**Furniture, Equipment and Leasehold Improvements** - The Organization capitalizes furniture, equipment and leasehold improvements with a cost of \$5,000 or greater. The cost of furniture and equipment is depreciated over the estimated useful life of the asset and is computed using the straight-line method. Leasehold improvements are amortized over the lives of the respective leases or the service lives of the improvements, whichever is shorter. Maintenance and repairs are charged to expense as incurred. Computer software purchased of \$25,000 or greater is capitalized and depreciated. Internally developed software and internally developed enhancements and modifications to existing or purchased software that result in additional functionality, with a total development cost in excess of \$500,000 are capitalized and depreciated.

## ***PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES***

### ***Notes to Consolidated Financial Statements***

***For the Years Ended December 31, 2012 and 2011***

---

#### ***Note 1 - Continued***

**Patent** - The donated patent is stated at the original assessed value less amortization computed on the straight-line method over the life of the patent.

**Vulnerability from Certain Concentrations** - Financial instruments that potentially subject the Organization to concentrations of credit and market risk consist primarily of cash and cash equivalents and investments. Cash and cash equivalents and investments held by financial institutions at times exceed Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insured limits.

For the years ended December 31, 2012 and 2011, 48% and 53%, respectively, of the Organization's total revenues, gains and other support was received from one private foundation, and 56% and 61%, respectively, of gross contributions and awards receivable are from one private foundation. For the years ended December 31, 2012 and 2011, 35% and 33%, respectively, of the Organization's total revenues, gains and other support consists of awards from the United States government, and 27% and 25%, respectively, of gross contributions and awards receivable is from the United States government. Management is aware of the related vulnerabilities but does not anticipate any losses in connection with these concentrations. Management continues to seek improved diversification from donors and funding sources.

**Contributions and Awards Revenue Recognition** - Unconditional contributions and awards from U.S. and foreign government agencies, foundations and public and private funders are recognized as temporarily restricted revenue at the time committed or obligated, provided the donor has identified a restriction on the use of the funds. Revenue from contracts is recognized at the time the service or good is provided.

**Donated Goods and Services** - Donations of goods, including property and equipment, are recorded as support at their estimated fair values at the date of donation. Such donations are reported as unrestricted support unless the donor has restricted the donated asset to a specific purpose. Donated services are recognized if the services received (i) create or enhance nonfinancial assets or (ii) require specialized skills, are provided by individuals possessing those skills and would need to be purchased if not provided by donation. In-kind donations totaled \$1.03 million and \$3.8 million for the years ended December 31, 2012 and 2011, respectively, and are included in management and general expense on the consolidated statements of unrestricted activities.

**Functional Allocation of Expenses** - The costs of providing the various programs and other activities have been summarized on a functional basis in the consolidated statements of unrestricted activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Additionally, the Organization incurs various fundraising expenses.

**Collaborations** - Awards, contracts and temporarily restricted contributions are used to fund projects related to global health. In connection with these projects, the Organization works with collaborating partners to assess health problems, identify and implement solutions and evaluate results. Accordingly, the Organization enters into funding agreements and cooperative agreements with these collaborating partners including international agencies, ministries of health, nongovernmental organizations, commercial entities, and universities, et cetera. Subagreements and subcontracts awarded from these projects are funded by temporarily restricted contributions to other organizations and recorded as expense, which totaled \$134.1 million and \$132.8 million for the years ended December 31, 2012 and 2011, respectively.

## PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011

---

#### Note 1 - Continued

**Tax Exempt Status** - The Internal Revenue Service has determined that PATH, PVS and PDS are exempt from federal income taxes under provisions of Section 501(c)(3) of the Internal Revenue Code (IRC). They are classified as organizations that are not private foundations under Section 501(a) of the IRC. FATH, as an independent nonprofit foundation within the meaning of Articles 80 *et seq* of the Swiss Civil Code, has been granted tax exemption by the Department of Finance. OATH, as an international charity fund, has been registered as such based on Article 157 Part 111 of the Tax Code of Ukraine. The Organization files tax returns with the United States and various state, local and foreign governments. The Organization is subject to tax examinations by the tax authorities of these governments for the current year and certain prior years based on the applicable laws and regulations of each jurisdiction.

**Foreign Currency Translation** - Substantially all assets and liabilities of the Organization that are held in foreign currencies are translated at year-end exchange rates. Revenues, gains and other support and expenses are translated at the average monthly exchange rates during the year. Gains and losses from foreign currency translation for the year are included in the statements of unrestricted activities and changes in net assets. Net foreign currency translation losses for the years ended December 31, 2012 and 2011, totaled \$275,000 and \$121,000, respectively.

**Use of Estimates** - The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Subsequent Events** - The Organization has evaluated subsequent events through May 10, 2013, the date on which the consolidated financial statements were available to be issued.

#### Note 2 - Cash and Cash Equivalents

Cash and cash equivalents consisted of the following at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Money market accounts and other cash equivalents	\$ 34,399	\$ 10,131
Cash	<u>6,054</u>	<u>8,091</u>
	<u><b>\$ 40,453</b></u>	<u><b>\$ 18,222</b></u>

When specified by funding agreement, the Organization holds project-related funds in separate bank accounts.

Cash and cash equivalents held in bank accounts outside of the United States totaled \$4.8 million and \$5.4 million at December 31, 2012 and 2011, respectively.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**  
**For the Years Ended December 31, 2012 and 2011**

---

**Note 3 - Investments**

Investments consisted of the following at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Corporate bonds	\$ 182,685	\$ 181,832
U.S., state, and foreign government securities	33,171	58,981
Government guaranteed corporate securities	5	7
Asset-backed securities	19,644	26,995
Equity securities	4,374	3,537
Commercial paper and short-term funds	35,470	27,514
Money market investment funds	6	5
	<u>\$ 275,355</u>	<u>\$ 298,871</u>

The return on cash and investments was comprised of the following for the years ended December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Interest and dividends	\$ 4,402	\$ 5,043
Unrealized gains (losses)	2,213	(1,972)
Realized losses	(808)	(803)
	<u>\$ 5,807</u>	<u>\$ 2,268</u>

## ***PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES***

### ***Notes to Consolidated Financial Statements***

***For the Years Ended December 31, 2012 and 2011***

---

#### ***Note 4 - Fair Value Measurements***

U.S. GAAP provides a framework for measuring fair value. To increase consistency and comparability in fair value measurements, the framework requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.

The framework uses a three-level valuation hierarchy based on observable and non-observable inputs. Observable inputs consist of data obtained from independent sources. Non-observable inputs reflect market assumptions. These two types of inputs are used to create the fair value hierarchy, giving preference to observable inputs.

Assets and liabilities classified as Level 1 have fair values based on unadjusted quoted market prices for identical instruments in active markets. Assets and liabilities classified as Level 2 have fair values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in inactive markets, or model-derived valuations whose inputs are observable. Assets and liabilities classified as Level 3 have fair values based on value drivers that are unobservable.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at December 31, 2012 and 2011.

Money Market Investment Funds - Valued at cost plus accrued interest, which approximates fair value.

Equity and Debt Mutual Funds - Valued at quoted market prices in active markets, which represent the net asset value (NAV) of shares held by the Organization at year-end.

Equity Securities - Valued at the closing price reported on the active market on which the securities are traded.

Debt Securities - Valued using bid evaluations from similar instruments in actively traded markets.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**For the Years Ended December 31, 2012 and 2011**

**Note 4 - Continued**

Assets recorded at fair value on a recurring basis were as follows at December 31, 2012:

	<i>(In Thousands)</i>			
	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Equity securities and equity mutual funds-				
Equity securities:				
Biopharmaceuticals	\$ 35	\$ -	\$ -	\$ 35
Equity mutual funds:				
Large blend	2,899			2,899
Large value	1,440			1,440
	<u>4,374</u>			<u>4,374</u>
Total equity securities and equity mutual funds	4,374			4,374
Debt securities and debt mutual funds-				
Debt securities:				
U.S. government		32,074		32,074
Foreign government		1,102		1,102
Corporate		179,220		179,220
Asset-backed securities		19,644		19,644
Short-term funds, bills and notes	35,470			35,470
Debt mutual funds:				
Multi-sector bond	3,465			3,465
	<u>38,935</u>	<u>232,040</u>		<u>270,975</u>
Total debt securities and debt mutual funds	38,935	232,040		270,975
Money market investment funds	6			6
	<u>6</u>			<u>6</u>
<b>Total Assets at Fair Value</b>	<b><u>\$ 43,315</u></b>	<b><u>\$ 232,040</u></b>	<b><u>\$ -</u></b>	<b><u>\$ 275,355</u></b>

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**For the Years Ended December 31, 2012 and 2011**

**Note 4 - Continued**

Assets recorded at fair value on a recurring basis were as follows at December 31, 2011:

	<i>(In Thousands)</i>			
	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Equity securities and equity mutual funds-				
Equity securities:				
Biopharmaceuticals	\$ 8	\$ -	\$ -	\$ 8
Equity mutual funds:				
Large blend	2,825			2,825
Large value	704			704
Total equity securities and equity mutual funds	3,537			3,537
Debt securities and debt mutual funds-				
Debt securities:				
U.S. government		54,880		54,880
Foreign government		4,108		4,108
Corporate		178,494		178,494
Asset-backed securities		26,995		26,995
Short-term bills and notes	23,515	3,999		27,514
Debt mutual funds:				
Multi-sector bond	3,338			3,338
Total debt securities and debt mutual funds	26,853	268,476		295,329
Money market investment funds	5			5
<b>Total Assets at Fair Value</b>	<b>\$ 30,395</b>	<b>\$ 268,476</b>	<b>\$ -</b>	<b>\$ 298,871</b>



**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2012 and 2011**

**Note 5 - Contributions and Awards Receivable**

Contributions and awards receivable consisted of the following at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Due in less than one year	\$ 212,563	\$ 226,938
Due in one to five years	<u>122,162</u>	<u>175,144</u>
	334,725	402,082
Less present value discount (0.6% - 4.8%)	(1,331)	(2,667)
Less allowance for doubtful accounts	<u>(216)</u>	<u>(232)</u>
	<u><b>\$ 333,178</b></u>	<u><b>\$ 399,183</b></u>

Awards from the U.S. government and certain nongovernment organizations are recorded as revenue when obligated, which may not reflect the full amount awarded. The total amount of unobligated awards pending for active projects was \$341.4 million and \$433.2 million at December 31, 2012 and 2011, respectively.

**Note 6 - Furniture, Equipment and Leasehold Improvements**

The Organization funds purchases of furniture, equipment and leasehold improvements from two sources: from the capital fund, a designated reserve of unrestricted net assets; or directly from temporarily restricted project funds.

Furniture, equipment and leasehold improvements consisted of the following at December 31:

	<i>2012 (In Thousands)</i>		
	<u>Capital Fund</u>	<u>Project Funds</u>	<u>Total</u>
Furniture	\$ 3,466	\$ -	\$ 3,466
Equipment	4,392	5,376	9,768
Leasehold improvements	<u>20,242</u>	<u>66</u>	<u>20,308</u>
	28,100	5,442	33,542
Less accumulated depreciation and amortization	<u>(9,638)</u>	<u>(3,092)</u>	<u>(12,730)</u>
	<u><b>\$ 18,462</b></u>	<u><b>\$ 2,350</b></u>	<u><b>\$ 20,812</b></u>

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2012 and 2011**

---

**Note 6 - Continued**

	<i>2011 (In Thousands)</i>		
	<i>Capital Fund</i>	<i>Project Funds</i>	<i>Total</i>
Furniture	\$ 3,471	\$ -	\$ 3,471
Equipment	4,791	4,886	9,677
Leasehold improvements	19,714		19,714
Construction in progress	145		145
	28,121	4,886	33,007
Less accumulated depreciation and amortization	(7,887)	(3,040)	(10,927)
	<b>\$ 20,234</b>	<b>\$ 1,846</b>	<b>\$ 22,080</b>

**Note 7 - Patent**

The Organization holds a patent for the UltraRice Technology for fortified rice originally valued at \$3.3 million. The patent was issued in March 1995 and expires in March 2015. The patent is being amortized over its expected useful life of 18.25 years. Accumulated amortization totaled \$2.9 million and \$2.7 million as of December 31, 2012 and 2011, respectively.

**Note 8 - Line of Credit**

The Organization has a revolving line of credit for up to \$1 million with a commercial bank for working capital purposes available through June 30, 2014. Interest on the line is at LIBOR plus 1.25%. The credit facility available to the Organization is reduced by Standby Letters of Credit (SBLC) under \$300,000 associated with various lease commitments. PATH has an additional SBLC for \$361,000 associated with a domestic lease commitment that was obtained in 2010. No amounts were outstanding under the line of credit or SBLCs at December 31, 2012 or 2011. The line of credit is secured by the Organization's personal property.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2012 and 2011**

**Note 9 - Notes Payable**

Notes payable consisted of the following at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Note payable to a commercial bank maturing December 1, 2014. Interest payments fluctuate based on the LIBOR rate BBA plus 1.65% (1.86% and 1.93% at December 31, 2012 and 2011, respectively). Principal is payable in monthly installments of \$41,667 with remaining balance due at maturity. The note is secured by the Organization's personal property. The note includes certain restrictive covenants including the requirement for the Organization to maintain certain financial ratios.	\$ 3,500	\$ 4,500
Program-related investment from a private foundation in the form of a note payable maturing November 2019. Interest is paid at a 2% fixed rate. Quarterly principal and interest payments of \$69,114 are required. The note is secured by the Organization's trade fixtures, equipment and furnishings. The note includes certain restrictive covenants including the requirement for the Organization to maintain certain financial ratios.	<u>1,732</u>	<u>1,480</u>
	<u><b>\$ 5,232</b></u>	<u><b>\$ 5,980</b></u>

Subsequent to December 31, 2012, the note payable to a commercial bank was modified to extend the maturity date to February 1, 2018. Effective March 1, 2013, interest will accrue at 1.86% on the outstanding balance, and principal will become payable in monthly installments of \$56,944.

Maturities of notes payable are as follows:

<i>For the Year Ending December 31,</i>	<u><i>(In Thousands)</i></u>
2013	\$ 896
2014	932
2015	937
2016	942
2017	947
Thereafter	<u>578</u>
	<u><b>\$ 5,232</b></u>

Interest expense on notes payable totaled \$102,000 and \$124,000 for the years ended December 31, 2012 and 2011, respectively.

## PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011

---

#### Note 10 - Self-Insurance Reserve

The Organization maintains a research insurance program made up of a Self-Insured Retention (SIR) reserve fund and an excess insurance policy. The Organization's SIR program covers claims up to \$250,000 per incident and is funded by allocations to programs that are conducting clinical trials involving human subjects. As of December 31, 2012, \$2.1 million has been funded and set aside in the reserve. It is anticipated that additional planned annual allocations and interest income will add to the reserve going forward. Additionally, the Organization carries an excess insurance policy to cover any potential claims from \$250,000 to \$10 million.

#### Note 11 - Unrestricted Net Assets

Unrestricted net assets consisted of the following at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Capital Fund	\$ 3,000	\$ 3,000
Catalyst Fund	4,007	2,990
Reach Fund	1,500	1,500
FIPI	14	40
Patent	403	582
Board Designated Endowment	2,792	2,459
FTT (Operations)	77	77
FTT (Corpus)	2,019	2,019
Self-Insured Retention Reserve	2,061	2,056
Special Project Fund	6	33
Undesignated	5,402	2,873
	<u>\$ 21,281</u>	<u>\$ 17,629</u>

The following is a description of board designated unrestricted net assets:

Capital Fund - Represents the portion of net assets attributed to the net book value of fixed assets and amounts designated for future purchases of fixed assets, net of any related loan balance.

Catalyst Fund - Represents a fund established by the Organization that consists of donor contributions that serve as a key source of innovation funding; funds that support new initiatives, leverage major grants and meet critical organizational needs.

Reach Fund - Represents a fund established by the Organization that consists of donor contributions to expand and deepen the Organization's geographic reach, accelerate the development and introduction of health technologies, deliver integrated packages of health solutions, and build organizational infrastructure including investing in people and systems for the future.

## PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES

### Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011

---

#### Note 11 - Continued

FIPI - The Fund for Intellectual Property and Innovation (FIPI) is a reserve generated by net royalty earnings and license fees resulting from the licensing and/or transfers of technologies. The funds are used for patent application and maintenance, and the advancement of technologies.

Patent - Represents the net value of the donated UltraRice Patent (Note 7).

Board Designated Endowment - The endowment that is included in unrestricted net assets represents amounts designated by the Board.

FTT (Operations) - The Fund for Technology Transfer (FTT) Operations fund is a reserve generated by net operating earnings of FTT. The reserve is used to supplement funding for operating costs.

FTT (Corpus) - The FTT Corpus fund represents funds available for lending. Funds are either out on loan or are invested in interest bearing accounts. Income on these funds is used for funding FTT Operations.

Self-Insured Retention Reserve - The amount funded to date to pay the Organization's share of any claims resulting from settlement or judgment of actions as a result of clinical trials (Note 10).

Special Project Fund - The special project fund is a reserve of unrestricted funding that will be applied to specific programs.

#### Note 12 - Temporarily Restricted Net Assets

Temporarily restricted net assets were available for the following purposes at December 31:

	<i>(In Thousands)</i>	
	<u>2012</u>	<u>2011</u>
Privately funded projects	\$ 436,250	\$ 490,730
U.S. government funded projects	62,748	75,497
Project funds generated from interest earnings	40,104	38,982
International government funded projects	28,406	33,164
International bi-lateral funded projects	19,497	14,324
Project equipment	2,339	2,153
Endowment earnings	1,640	1,040
	<u>\$ 590,984</u>	<u>\$ 655,890</u>

Restricted funds are available for projects specified by donors and are focused primarily on global health initiatives.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**For the Years Ended December 31, 2012 and 2011**

**Note 13 - Endowment**

The Organization's endowment consists of a number of funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the Board to function as an endowment (quasi-endowment). As required by U.S. GAAP, net assets associated with endowment funds, including quasi-endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board of Directors of the Organization has adopted the provisions of the Washington State Prudent Management of Institutional Funds Act (PMIFA). The Organization has interpreted the law as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Organization classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, and (b) the original value of subsequent gifts to the permanent endowment. The remaining portion of the donor-restricted endowment fund that is not classified in the permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditures by the Organization in a manner consistent with the standard of prudence described by PMIFA.

In accordance with PMIFA, the Organization considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: 1) duration and preservation of the endowment fund; 2) the purposes of the Organization and the endowment fund; 3) general economic conditions; 4) effect of inflation or deflation; 5) the expected total return from income and the appreciation of investments; 6) other resources of the Organization; and, 7) the investment policy of the Organization.

Endowment net assets consisted of the following at December 31:

	<i>2012 (In Thousands)</i>			<i>Total</i>
	<i>Unrestricted</i>	<i>Temporarily Restricted</i>	<i>Permanently Restricted</i>	
Donor restricted endowment funds	\$ -	\$ 1,640	\$ 3,375	\$ 5,015
Board designated quasi-endowment funds	2,792			2,792
	<b><u>\$ 2,792</u></b>	<b><u>\$ 1,640</u></b>	<b><u>\$ 3,375</u></b>	<b><u>\$ 7,807</u></b>

	<i>2011 (In Thousands)</i>			<i>Total</i>
	<i>Unrestricted</i>	<i>Temporarily Restricted</i>	<i>Permanently Restricted</i>	
Donor restricted endowment funds	\$ -	\$ 1,040	\$ 3,370	\$ 4,410
Board designated quasi-endowment funds	2,459			2,459
	<b><u>\$ 2,459</u></b>	<b><u>\$ 1,040</u></b>	<b><u>\$ 3,370</u></b>	<b><u>\$ 6,869</u></b>

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements  
For the Years Ended December 31, 2012 and 2011**

**Note 13 - Continued**

Changes to endowment net assets are as follows for the years ended December 31, 2012 and 2011:

	<i>(In Thousands)</i>			
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Endowment net assets, January 1, 2011	\$ 2,389	\$ 916	\$ 3,367	\$ 6,672
Endowment investment return-				
Interest and dividends	67	118		185
Realized and unrealized gains	<u>3</u>	<u>6</u>		<u>9</u>
Total endowment investment return	70	124		194
Contributions			<u>3</u>	<u>3</u>
<b>Endowment Net Assets, December 31, 2011</b>	<b>2,459</b>	<b>1,040</b>	<b>3,370</b>	<b>6,869</b>
Endowment investment return-				
Interest and dividends	69	125		194
Realized and unrealized gains	<u>264</u>	<u>475</u>		<u>739</u>
Total endowment investment return	333	600		933
Contributions			<u>5</u>	<u>5</u>
<b>Endowment Net Assets, December 31, 2012</b>	<b><u>\$ 2,792</u></b>	<b><u>\$ 1,640</u></b>	<b><u>\$ 3,375</u></b>	<b><u>\$ 7,807</u></b>

## ***PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES***

### ***Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011***

---

#### ***Note 13 - Continued***

The Organization has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Organization must hold in perpetuity or for donor-specified periods as well as board designated funds. Under this policy, as approved by the Board of Directors, the endowment assets are invested in mutual funds to ensure a broad diversification among investment styles, sectors, industries, market capitalizations and credit quality. These vehicles offer the advantages of economies of scale, greater liquidity, broader diversification, cost efficiency, lower transaction costs and low minimum investment requirements not available through separate account management. The performance objective for the total endowment investment portfolio is to achieve an annualized investment return, net of fees, which will exceed a composite index composed of 40% Barclays Capital Aggregate Index and 60% S&P 500 Index. Performance is monitored quarterly over rolling one-year, three-year and five-year periods. The Organization expects its endowment funds, over time, to provide an average rate of return of approximately 5% annually. Actual returns in any given year may vary from this amount based on current market conditions.

To satisfy its long-term rate-of-return objectives, the Organization relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Organization targets a diversified asset allocation between two asset classes: 40% fixed income and 60% equity investments to achieve its long-term return objectives within prudent risk constraints.

The Organization has established an endowment spending policy for appropriating a maximum distribution in support of PATH's programs each year. In establishing this policy, the Organization considered the long-term expected return on its endowment and the need for that return to provide additional protection for any necessary adjustment to the value of the endowment for inflation. In order to sustain the real value of the endowment, the long-term return of the endowment should meet or exceed spending plus inflation as measured by an appropriate benchmark, such as the Consumer Price Index (CPI). To protect the essential value of the endowment against the expected impact of inflation, the Finance Committee sets a payout rate for the endowment's income that provides a prudent rate of real growth of endowment funds while also providing a relatively constant funding stream in support of PATH's current expenditures for programs. In determining each year's level of distribution, PATH will be governed by a spending policy which seeks to distribute up to 5% of the market value of the endowment investment portfolio, calculated based on the prior year's ending balance. This is consistent with the Organization's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return. There was no appropriation made during the years ended December 31, 2012 or 2011, due to market factors.



**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**For the Years Ended December 31, 2012 and 2011**

---

**Note 14 - Project Revenue**

The Organization has received several awards from The Department for International Development (DFID), United Kingdom of Great Britain and Northern Ireland, to support specific projects. DFID requires separate disclosure of revenue recognized in the Organization's financial statements. Unrestricted revenue recognized, including releases of restriction, for each of these projects is as follows for the year ended December 31, 2012:

	<u>(In Thousands)</u>
Aid as a Competitive Business: Historical Analysis of Competition Among Global Health Strategies and Emerging Opportunities for Innovation (contract 40040866)	\$ 22
Product Development Partnership (PDP) Arrangement for 2010-2015- Meningococcal Conjugate Vaccines	1,995
Maximizing the Quality of Scaling up Nutrition Programmes	734
Product Development Partnership (PDP) Arrangement for 2009-2013- New Vaccines for Diarrheal Diseases	1,889
Product Development Partnership (PDP) Arrangement for 2009-2014	1,089
Reproductive Health Supplies Coalition: Developing Affordable, Quality Reproductive Health Commodities - Purchase Order 40068171	463
Reproductive Health Supplies Coalition: Quality Reproductive Health Medicines- Product Component Code 202825-101	<u>1,857</u>
	<u><b>\$ 8,049</b></u>

Revenue for these awards is released from restriction as related allowable project costs are incurred and is included in contribution and award revenue on the consolidated statements of activities and changes in net assets.

## **PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

### **Notes to Consolidated Financial Statements For the Years Ended December 31, 2012 and 2011**

---

#### **Note 15 - Employee Benefits**

The Organization sponsors a defined contribution 401(k) plan (the Plan). Under the Plan, PATH employees may elect to contribute up to 75% of their pre-tax compensation, subject to certain limits under the Internal Revenue Code. The Organization will match the employee's contribution monthly at a ratio of 1:1 for the first 2%, and 2:1 for the next 4%, with a maximum employer contribution equal to 4% of pre-tax salary. Employer matching contributions to the Plan are fully vested after one year of completed service. Employee optional contributions in the Plan vest immediately. In addition, the Organization may make a voluntary employer contribution of up to 8% of employees' base compensation. Voluntary employer contributions to the Plan vest at a rate of 20% for each completed year of service. All regular U.S. hire employees are eligible to enter the Plan on the first of the month after completing three months of employment. The Organization also offers an optional Roth 401(k) plan.

Employer contributions for both U.S.-based plans totaled \$5.3 million and \$4.2 million for the years ended December 31, 2012 and 2011, respectively. Total global pension costs totaled \$6.4 million and \$5 million for the years ended December 31, 2012 and 2011, respectively.

#### **Note 16 - Commitments and Contingencies**

**Operating Leases** - A summary of annual noncancelable minimum commitments under operating leases for office space and equipment is as follows:

<i>For the Year Ending December 31,</i>	<i>(In Thousands)</i>
2013	\$ 7,298
2014	7,117
2015	6,859
2016	6,700
2017	6,836
Thereafter	41,982
	<u>\$ 76,792</u>

Rental expense was \$7.8 million and \$9.3 million in 2012 and 2011, respectively.

**Awarding Agencies** - Expenses incurred under certain programs are subject to audit by the awarding agencies. If, as a result of such audit, certain expenses incurred are determined to be nonreimbursable, the Organization may be liable for repayment of disallowed expenses previously claimed or received.

**Guarantee** - The Organization entered into an agreement whereby it agreed to participate as a guarantor in a microcredit loan guarantee program. Losses realized on the microcredit loans will be allocated pro rata to each guarantor in the program; however, the Organization's maximum commitment and obligation to the program will not exceed \$1 million. The obligation under this program is with full recourse to the Organization. Under the terms of the agreement, the Organization will remain in the program until it provides advance written notice of withdrawal. Commitment may then be withdrawn after 18 months following the Organization's notice. No liability or loss has been recorded in the Organization's 2012 or 2011 financial statements related to this guarantee.

**PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH) AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**For the Years Ended December 31, 2012 and 2011**

---

**Note 17 - Acquisition of PATH Drug Solutions**

On January 1, 2012, PATH Drug Solutions (PDS), previously known as Institute for OneWorld Health, became a controlled affiliate of PATH. PDS brings its drug development expertise and experience in neglected infectious diseases to bear on PATH's mission of improving global health through innovation. By becoming a PATH affiliate, PDS will be able to scale and accelerate its successful drug development efforts, which include developing a semi synthetic version of artemisinin, a key component in treating malaria, to help provide an affordable, stable source of the drug, alleviate shortages, and meet global demand. PDS, based in South San Francisco, was founded in 2000 and became the first nonprofit pharmaceutical company in the United States. PDS, which also has offices in New Delhi and Patna, India, currently works on drug development projects for diseases that include diarrheal disease, malaria, and visceral leishmaniasis, a parasitic disease spread by sand flies. PDS will remain a nonprofit organization operating out of its South San Francisco headquarters.

PATH has accounted for this transaction as an acquisition in accordance with U.S. GAAP; therefore, the financial statements of PDS are included in PATH's consolidated financial statements effective January 1, 2012. The Organization recognized an inherent of \$35.4 million contribution, which represents the fair value of the net assets of PDS on January 1, 2012. The fair value of PDS assets acquired and liabilities assumed on that date were as follows:

	<u>(In Thousands)</u>
Cash and investments	\$ 23,045
Contributions and award receivable	13,320
Other assets	567
Accounts payable and accrued expenses	<u>(1,582)</u>
	<u><b>\$ 35,350</b></u>